Tumor-Antagonizing Fibroblasts Secrete Prolargin as Tumor Suppressor in Hepatocellular Carcinoma
Chiavarina, B.; Ronca, R.; Otaka, Y.; Sutton, R. B.; Rezzola, S.; Yokobori, T.; Chiodelli, P.; Souche, R.; Maraver, A.; Faa, G.; Oyama, T.; Gofflot, S.; Bellahcene, A.; Detry, O.; Delvenne, P.; Castronovo, V.; Nishiyama, M.; Turtoi, A.
Show abstract
Systemic treatment of hepatocellular carcinoma (HCC) targets the tumor microenvironment (TME) by combining immunotherapy with angiogenesis inhibitors. Cancer-associated fibroblasts (CAF) are important components of the TME, however their targeting in clinics remains challenging. To this end, the existence of tumor supressing CAF and their poor characterisation is a major conundrum. Starting from proteomics and single cell analysis, we outline CAF heterogeneity in HCC and describe a subtype of CAF that express a novel tumor-related protein prolargin. Upon secretion prolargin is deposited in the TME where its levels positively correlate with patient outcome (HR=0.37; p=0.01). In vivo, tumors with lower prolargin expression display faster progression (5-fold; p=0.01) and stronger angiogenesis. Mechanistically, aggressive HCC cells degrade prolargin using matrix metalloprotease 3 (MMP3). We show that prolargin binds and inhibits several growth factors, key to tumor progression. Inhibiting prolargin degradation combined with sorafenib, demonstrated superior tumor control compared to sorafenib treatment alone. In conclusion, prolargin-expressing CAF have tumor-antagonizing properties. Stabilizing prolargin tumoral levels should be considered for systemic therapy of HCC, involving CAF in existing TME targeting.
Matching journals
The top 15 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Prognosis-related molecular subtypes and immune features associated with hepatocellular carcinoma 93%
- Uncovering novel roles of miR-122 in the pathophysiology of the liver: Potential interaction with NRF1 and E2F4 signaling 93%
- The epithelial-mesenchymal transcription factor SNAI1 represses transcription of the tumor suppressor miRNA let-7 in cancer 92%
Similar papers in this journal
- Versatile roles of Annexin A4 in ccRCC: impact on membrane repair, transcriptional signatures, and composition of the tumor microenvironment 95%
- Inhibition of Extracellular Vesicle-Associated MMP2 Abrogates Intercellular Transfer of Hepatic miR-122 to Tissue Macrophages and Curtails Liver Inflammation 93%
- Matrix structure and microenvironment dynamics correlate with chemotherapy response in ovarian cancer 93%
Similar papers in this journal
- HKDC1 Promotes Liver Cancer Stemness Under Hypoxia via Stabilizing β-Catenin 96%
- A Developmentally Prometastatic Niche to Hepatoblastoma in Neonatal Liver mediated by the Cxcl1/Cxcr2 Axis 95%
- Vascular damage and excessive proliferation compromise liver function after extended hepatectomy in mice 92%
Similar papers in this journal
- Diet-induced rewiring of the Wnt gene regulatory network connects aberrant splicing to fatty liver and liver cancer in DIAMOND mice 93%
- Simulating the human tumor microenvironment in colorectal cancer organoids in vitro and in vivo 93%
- Long-term maintenance of patient-specific characteristics in tumoroids from six cancer indications in a common base culture media system 93%